Aprogen Biologics: Persistent Losses, No Shareholder Returns, Potential Dilution from 130B Won Convertible Bonds, and Poor Corporate Governance
Consolidated net loss of 168.3B KRW in the latest period, marking three consecutive years of large deficits; operating loss of 60.4B KRW indicates no improvement in profitability.
No shareholder returns including dividends for the past three fiscal years; no dividend policy or plan established, providing no predictability to shareholders.
Outstanding convertible bonds totaling 130B KRW (Issues 16–19) with conversion prices (₩3,375–₩8,290) mostly above the current stock price (₩3,165); if conversion occurs upon price recovery, up to 390M new shares could be issued, causing dilution.
At the 67th AGM, capital reduction and treasury share disposal plans were passed with 100% approval; reduction in shares may partially offset dilution for existing shareholders.
13 out of 15 corporate governance core indicators not complied with (e.g., failure to convene AGM 4 weeks in advance, no electronic voting, meeting on concentrated date, outside director ratio only 25%, all-male board).
No board committees (audit, compensation, etc.), no CEO succession policy, no enterprise risk management policy; internal audit function lacks accounting/finance expertise.
Related-party loans and borrowings of approximately 90.7B KRW and 199.7B KRW respectively, with inadequate internal transaction controls; approvals done individually without blanket board resolution.
No value-up plan disclosed; shareholder communication limited to phone calls with no formal IR or conference calls.
[AI Summary]Aprogen Biologics exhibits multiple negative signals including persistent losses, absence of shareholder returns, potential dilution from convertible bonds, and widespread non-compliance with corporate governance standards. While the capital reduction is a positive step, fundamental profitability improvement and transparent governance are essential to restore investor confidence and stock price recovery.